BR112016005361A8 - inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos - Google Patents

inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos

Info

Publication number
BR112016005361A8
BR112016005361A8 BR112016005361A BR112016005361A BR112016005361A8 BR 112016005361 A8 BR112016005361 A8 BR 112016005361A8 BR 112016005361 A BR112016005361 A BR 112016005361A BR 112016005361 A BR112016005361 A BR 112016005361A BR 112016005361 A8 BR112016005361 A8 BR 112016005361A8
Authority
BR
Brazil
Prior art keywords
gyrase inhibitors
packaging
composition
well
dosage form
Prior art date
Application number
BR112016005361A
Other languages
English (en)
Other versions
BR112016005361B8 (pt
BR112016005361B1 (pt
Inventor
John Borchardt Allen
Bensen Daniel
Phillipison Douglas
C Lightstone Felice
Finn John
Zhang Junhu
William Tari Leslie
Trzoss Michael
Teng Min
E Wong Sergio
Joong Lee Suk
To Lam Thanh
B Nguyen Toan
Ong Voon
Li Xiaoming
Chen Zhiyong
Original Assignee
L Livermore Nat Security Llc
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L Livermore Nat Security Llc, Merck Sharp & Dohme filed Critical L Livermore Nat Security Llc
Publication of BR112016005361A8 publication Critical patent/BR112016005361A8/pt
Publication of BR112016005361B1 publication Critical patent/BR112016005361B1/pt
Publication of BR112016005361B8 publication Critical patent/BR112016005361B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

resumo inibidores de girase tricíclica são aqui divulgados compostos tendo a estrutura de fórmula i e sais, ésteres e pró-fármacos farmaceuticamente adequados dos mesmos que são úteis como inibidores da girase tricíclica antibacterianamente eficazes. composições farmacêuticas, usos e métodos relacionados de preparação dos compostos são também contemplados.
BR112016005361A 2013-09-11 2014-09-10 Composto, composição, e, uso de um composto BR112016005361B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361876688P 2013-09-11 2013-09-11
US61/876,688 2013-09-11
PCT/US2014/055019 WO2015038661A1 (en) 2013-09-11 2014-09-10 Tricyclic gyrase inhibitors

Publications (3)

Publication Number Publication Date
BR112016005361A8 true BR112016005361A8 (pt) 2018-01-30
BR112016005361B1 BR112016005361B1 (pt) 2022-12-27
BR112016005361B8 BR112016005361B8 (pt) 2023-04-18

Family

ID=52666234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016005361A BR112016005361B8 (pt) 2013-09-11 2014-09-10 Composto, composição, e, uso de um composto

Country Status (8)

Country Link
US (1) US10385055B2 (pt)
EP (1) EP3044225A4 (pt)
CN (1) CN105899511B (pt)
AU (1) AU2014318838B2 (pt)
BR (1) BR112016005361B8 (pt)
RU (1) RU2680138C2 (pt)
WO (1) WO2015038661A1 (pt)
ZA (1) ZA201601628B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103562208B (zh) * 2011-03-15 2016-08-31 默沙东公司 三环促旋酶抑制剂
US10865216B2 (en) * 2012-09-12 2020-12-15 Merck Sharp & Dohme Corp. Tricyclic Gyrase inhibitors
CN110446699A (zh) 2017-03-24 2019-11-12 大正制药株式会社 2（1h）-喹啉酮衍生物
EP3601282B1 (en) 2017-03-30 2021-07-21 F. Hoffmann-La Roche AG Novel pyrido[2,3-b]indole compounds for the treatment and prophylaxis of bacterial infection
CN110801455B (zh) * 2019-11-12 2020-06-02 河北医科大学第二医院 用于治疗mrsa的药物组合物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2158127C2 (ru) * 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US6874491B2 (en) 2003-01-15 2005-04-05 William Bednar Crossbow rope cocking device
US20080051414A1 (en) 2003-10-14 2008-02-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US7326712B2 (en) * 2003-10-14 2008-02-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
US20090143399A1 (en) 2003-10-14 2009-06-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US7982035B2 (en) * 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
CN103562208B (zh) * 2011-03-15 2016-08-31 默沙东公司 三环促旋酶抑制剂
US10865216B2 (en) * 2012-09-12 2020-12-15 Merck Sharp & Dohme Corp. Tricyclic Gyrase inhibitors

Also Published As

Publication number Publication date
ZA201601628B (en) 2017-06-28
AU2014318838B2 (en) 2018-06-07
WO2015038661A1 (en) 2015-03-19
AU2014318838A1 (en) 2016-03-24
EP3044225A4 (en) 2017-03-08
BR112016005361B8 (pt) 2023-04-18
CN105899511A (zh) 2016-08-24
EP3044225A1 (en) 2016-07-20
RU2680138C2 (ru) 2019-02-18
RU2016113494A (ru) 2017-10-16
US20160222015A1 (en) 2016-08-04
US10385055B2 (en) 2019-08-20
BR112016005361B1 (pt) 2022-12-27
RU2016113494A3 (pt) 2018-05-31
CN105899511B (zh) 2019-06-07

Similar Documents

Publication Publication Date Title
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
NI201400108A (es) Compuestos de heterociclilo
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CO2018002211A2 (es) Piridinona dicarboxamida para su uso como inhibidores de bromodominio
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112013023266A8 (pt) Inibidores da girase tricíclicos
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
EA201301240A1 (ru) Полиморфная форма бензоата линаглиптина
GT201400059A (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, proceidmientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparacion de medicamentos
BR112016009488A8 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica.
DOP2015000170A (es) Compuestos químicos
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
CR20150007A (es) Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112016005361A8 (pt) inibidores de girase tricíclica, composição, forma de dosagem, embalagem e dispositivo dispensador que os compreende, bem como uso dos mesmos
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
BR112016005317A2 (pt) derivados de quinazolina e seu uso como inibidores de dna metiltransferase
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
EA201591259A1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
BR112015015250A2 (pt) derivados de pirrolidina, composições farmacêuticas e usos dos mesmos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/09/2014, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: LAWRENCE LIVERMORE NATIONAL SECURITY, LLC (US) ; MERCK SHARP AND DOHME LLC (US)